Merus to Participate in Upcoming Investor Conferences
- Citi’s 16th Annual
BioPharma Virtual Conference(Panel discussion): Thursday, Sept. 9, 2021at 1:25-2:25 p.m. ET H.C. Wainwright23rd Annual Global Investment Conference(Presentation): Pre-recorded and available starting September 13at 7:00 a.m. ET
Cantor Virtual Global Healthcare(Presentation): Monday, September 27, 2021at 2:40-3:10 p.m. ET
The webcast of the presentations will be available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Investor and Media Inquiries:
Kathleen FarrenMerus N.V. Communications Specialist 617-230-4165 email@example.com